Skip to content

Effect of vitamin D supplementation on serum 25-hydroxyvitamin D levels, inflammatory biomarkers and total antioxidant capacity in different types of vitamin D receptor polymorphisms in breast cancer women

Effect of vitamin D supplementation on serum 25-hydroxyvitamin D levels, inflammatory biomarkers and total antioxidant capacity in different types of vitamin D receptor polymorphisms in breast cancer women

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015090623924N1
Enrollment
46
Registered
2015-10-08
Start date
2015-09-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer. Malignant neoplasm of breast

Interventions

Intervention 1: Placebo, one time per week for 2 months. Intervention 2: Vitamin D, 50,000 IU, one time per week for 2 months.
Placebo
Treatment - Drugs
Placebo, one time per week for 2 months
Vitamin D, 50,000 IU, one time per week for 2 months

Sponsors

Vice Chancellor for Research of Ahvaz Jundishapur University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: all women who were diagnosed with stage ? breast cancer; age>20 years; 23< BMI<30; not consuming any kinds of vitamin D supplements during last 3 month; not getting any medication that affect serum vitamin D status. Exclusion criteria: the presence of any underlying disease (liver, kidney and HIV); a history of chemotherapy or radiotherapy for any reason except for current cancer; treatment with Corticosteroids; pregnancy and lactation; chronic diarrhea and malabsorption; non-iranian races (foreigners).

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Tumor Necrosis Factor alpha. Timepoint: At the beginning and the end of the study. Method of measurement: ELISA.;Transforming Growth Factor beta. Timepoint: At the beginning and the end of the study. Method of measurement: ELISA.;Total Antioxidant Capacity. Timepoint: At the beginning and the end of the study. Method of measurement: ELISA.;25 (OH) D. Timepoint: At the beginning and the end of the study. Method of measurement: ELISA.;Vitamin D receptor polymorphisms (FOK1? Bsml1? Taq? Apa1). Timepoint: At the beginning of the study. Method of measurement: PCR.

Secondary

MeasureTime frame
Antropometric Measurments (height, weight and waist circumferences). Timepoint: at the baseline and after 8 weeks of intervention. Method of measurement: Height, hip and waist circumferences in cm and weight in kg by standard method.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHoura Mohseni

Ahvaz Jundishapur University of Medical Sciences

houra.mohseni@yahoo.com+98 61 3336 7543

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 8, 2026